Modulation of amyloid precursor protein processing by synthetic ceramide analogues

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 8, 2010, Pages 887-895

  Li, Hongyun ^a   Kim, Woojin S ^a,b   Guillemin, Gilles J ^b   Hill, Andrew F ^c,d   Evin, Genevieve ^e   Garner, Brett ^a,f  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid beta peptide; Glycosphingolipid; Neurodegeneration; Sphingolipids

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; AMYLOID PRECURSOR PROTEIN; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE; THREO 2 HEXADECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL VIABILITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LIPID METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CERAMIDES; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXINS; FETUS; HUMANS; MEPERIDINE; MODELS, BIOLOGICAL; MORPHOLINES; NEURONS; PROPANOLAMINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLIDINES;

CRICETULUS GRISEUS;

EID: 77953275293     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.05.012     Document Type: Article

References (59)

1. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
2. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
3. Kerr M.L., and Small D.H. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. J. Neurosci. Res. 80 (2005) 151-159
4. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., Christie G., Davis J.B., George A., Karran E.H., and Howlett D.R. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348 Pt 1 (2000) 137-144
5. Hung L.W., Ciccotosto G.D., Giannakis E., Tew D.J., Perez K., Masters C.L., Cappai R., Wade J.D., and Barnham K.J. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J. Neurosci. 28 (2008) 11950-11958
6. Bales K.R., Du Y., Holtzman D., Cordell B., and Paul S.M. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol. Aging 21 (2000) 427-432 discussion 451-423
7. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschape J.A., De Strooper B., Muller U., Shen J., and Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7 (2005) 1118-1123
8. Smith D.G., Cappai R., and Barnham K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 1768 (2007) 1976-1990
9. Evin G., Sernee M.F., and Masters C.L. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20 (2006) 351-372
10. Sastry P.S. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 24 (1985) 69-176
11. Op Den Velde W., and Hooghwinkel G.J. The brain ganglioside pattern in presenile and senile dementia. J. Am. Geriatr. Soc. 23 (1975) 301-303
12. Gottfries C.G., Adolfsson R., Aquilonius S.M., Carlsson A., Eckernas S.A., Nordberg A., Oreland L., Svennerholm L., Wiberg A., and Winblad B. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol. Aging 4 (1983) 261-271
13. Cuello A.C., Garofalo L., Kenigsberg R.L., and Maysinger D. Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons. Proc. Natl Acad. Sci. USA 86 (1989) 2056-2060
14. Fusco M., Vantini G., Schiavo N., Zanotti A., Zanoni R., Facci L., and Skaper S.D. Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives. Ann. NY Acad. Sci. 695 (1993) 314-317
15. Garofalo L., and Cuello A.C. Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp. Neurol. 125 (1994) 195-217
16. Svennerholm L. Gangliosides-a new therapeutic agent against stroke and Alzheimer's disease. Life Sci. 55 (1994) 2125-2134
17. Augustinsson L.E., Blennow K., Blomstrand C., Brane G., Ekman R., Fredman P., Karlsson I., Kihlgren M., Lehmann W., Lekman A., Mansson J.E., Ramstrom I., Wallin A., Wikkelso C., Gottfries C.G., and Svennerholm L. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement. Geriatr. Cogn. Disord. 8 (1997) 26-33
18. Yuki N., Sato S., Miyatake T., Sugiyama K., Katagiri T., and Sasaki H. Motoneuron-disease-like disorder after ganglioside therapy. Lancet 337 (1991) 1109-1110
19. Schwerer B., Pichler S., Bernheimer H., Safoschnik G., and Potzl G. Chronic progressive motor polyneuropathy after ganglioside treatment. J. Neurol. Neurosurg. Psychiatry 57 (1994) 238
20. Flicker C., Ferris S.H., Kalkstein D., and Serby M. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am. J. Psychiatry 151 (1994) 126-129
21. Ala T.A., Perfetti P.A., and Frey II W.H. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms. J. Neuroimmunol. 53 (1994) 109-113
22. Yanagisawa K., Odaka A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995) 1062-1066
23. Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C.A., Selkoe D.J., Naiki H., and Yanagisawa K. A seed for Alzheimer amyloid in the brain. J. Neurosci. 24 (2004) 4894-4902
24. Bernardo A., Harrison F.E., McCord M., Zhao J., Bruchey A., Davies S.S., Jackson Roberts II L., Mathews P.M., Matsuoka Y., Ariga T., Yu R.K., Thompson R., and McDonald M.P. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol. Aging 30 (2009) 1777-1791
25. Martins I.C., Kuperstein I., Wilkinson H., Maes E., Vanbrabant M., Jonckheere W., Van Gelder P., Hartmann D., D'Hooge R., De Strooper B., Schymkowitz J., and Rousseau F. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27 (2008) 224-233
26. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., and Simons K. Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 280 (2005) 36815-36823
27. Osenkowski P., Ye W., Wang R., Wolfe M.S., and Selkoe D.J. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J. Biol. Chem. 283 (2008) 22529-22540
28. Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., and Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280 (2005) 28110-28117
29. 3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase. J. Lipid Res. 32 (1991) 713-722
30. Lee L., Abe A., and Shayman J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274 (1999) 14662-14669
31. Abe A., Gregory S., Lee L., Killen P.D., Brady R.O., Kulkarni A., and Shayman J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105 (2000) 1563-1571
32. Glaros E.N., Kim W.S., Rye K.A., Shayman J.A., and Garner B. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J. Lipid Res. 49 (2008) 1677-1681
33. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., and Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 (2006) 17670-17680
34. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
35. Kim W.S., Suryo Rahmanto A., Kamili A., Rye K.A., Guillemin G.J., Gelissen I.C., Jessup W., Hill A.F., and Garner B. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein-E discs and suppression of amyloid-beta peptide generation. J. Biol. Chem. 282 (2007) 2851-2861
36. Sharples R.A., Vella L.J., Nisbet R.M., Naylor R., Perez K., Barnham K.J., Masters C.L., and Hill A.F. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 22 (2008) 1469-1478
37. Kerr S.J., Armati P.J., Guillemin G.J., and Brew B.J. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12 (1998) 355-363
38. Glaros E.N., Kim W.S., Quinn C.M., Wong J., Gelissen I., Jessup W., and Garner B. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apoA-I pathway. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J. Biol. Chem. 280 (2005) 24515-24523
39. Wing D.R., Garner B., Hunnam V., Reinkensmeier G., Andersson U., Harvey D.J., Dwek R.A., Platt F.M., and Butters T.D. High-performance liquid chromatography analysis of ganglioside carbohydrates at the pmol level after ceramide glycanse digestion and fluorescent labelling with 2-aminobenzamide. Anal. Biochem. 298 (2001) 207-217
40. Abe A., Radin N.S., Shayman J.A., Wotring L.L., Zipkin R.E., Sivakumar R., Ruggieri J.M., Carson K.G., and Ganem B. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36 (1995) 611-621
41. Bieberich E., Freischutz B., Suzuki M., and Yu R.K. Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J. Neurochem. 72 (1999) 1040-1049
42. Wogulis M., Wright S., Cunningham D., Chilcote T., Powell K., and Rydel R.E. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25 (2005) 1071-1080
43. Ronicke R., Klemm A., Meinhardt J., Schroder U.H., Fandrich M., and Reymann K.G. Abeta mediated diminution of MTT reduction-an artefact of single cell culture?. PLoS ONE 3 (2008) e3236
44. Basu S., Ma R., Mikulla B., Bradley M., Moulton C., Basu M., Banerjee S., and Inokuchi J. Apoptosis of human carcinoma cells in the presence of inhibitors of glycosphingolipid biosynthesis: I. Treatment of Colo-205 and SKBR3 cells with isomers of PDMP and PPMP. Glycoconj. J. 20 (2004) 157-168
45. Gylys K.H., Fein J.A., Yang F., Miller C.A., and Cole G.M. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging 28 (2007) 8-17
46. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Mansson J.E., and Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92 (2005) 171-182
47. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
48. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Mathews P.M., Noble W., Matsuoka Y., and Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 23 (2003) 5645-5649
49. Nixon R.A. Niemann-Pick type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol. 164 (2004) 757-761
50. Jin L.W., Shie F.S., Maezawa I., Vincent I., and Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 164 (2004) 975-985
51. Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury Jr. P.T., and Kosik K.S. A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4 (1998) 730-734
52. Vetrivel K.S., Cheng H., Kim S.H., Chen Y., Barnes N.Y., Parent A.T., Sisodia S.S., and Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 280 (2005) 25892-25900
53. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., and Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 100 (2003) 11735-11740
54. Tun H., Marlow L., Pinnix I., Kinsey R., and Sambamurti K. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J. Mol. Neurosci. 19 (2002) 31-35
55. Cheng H., Vetrivel K.S., Gong P., Meckler X., Parent A., and Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nat. Clin. Pract. Neurol. 3 (2007) 374-382
56. Zha Q., Ruan Y., Hartmann T., Beyreuther K., and Zhang D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9 (2004) 946-952
57. Inokuchi J., Mizutani A., Jimbo M., Usuki S., Yamagishi K., Mochizuki H., Muramoto K., Kobayashi K., Kuroda Y., Iwasaki K., Ohgami Y., and Fujiwara M. Up-regulation of ganglioside biosynthesis, functional synapse formation, and memory retention by a synthetic ceramide analog (l-PDMP). Biochem. Biophys. Res. Commun. 237 (1997) 595-600
58. Yamagishi K., Mishima K., Ohgami Y., Iwasaki K., Jimbo M., Masuda H., Igarashi Y., Inokuchi J., and Fujiwara M. A synthetic ceramide analog ameliorates spatial cognition deficit and stimulates biosynthesis of brain gangliosides in rats with cerebral ischemia. Eur. J. Pharmacol. 462 (2003) 53-60
59. Hisaki H., Shimasaki H., Ueta N., Kubota M., Nakane M., Nakagomi T., Tamura A., and Masuda H. In vivo influence of ceramide accumulation induced by treatment with a glucosylceramide synthase inhibitor on ischemic neuronal cell death. Brain Res. 1018 (2004) 73-77